RAPT Therapeutics (NASDAQ:RAPT) Earns "Neutral" Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports.

A number of other equities research analysts have also issued reports on RAPT. UBS Group decreased their price target on RAPT Therapeutics from $10.00 to $2.00 and set a "neutral" rating for the company in a research note on Monday, September 9th. Piper Sandler cut shares of RAPT Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $8.00 to $2.00 in a report on Monday. Finally, JPMorgan Chase & Co. downgraded shares of RAPT Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, RAPT Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $14.38.

RAPT Therapeutics Stock Down 0.6 %

Shares of NASDAQ:RAPT traded down $0.01 during midday trading on Tuesday, hitting $1.74. The stock had a trading volume of 2,388,083 shares, compared to its average volume of 754,171. The company has a market cap of $60.73 million, a P/E ratio of -0.62 and a beta of 0.33. RAPT Therapeutics has a 12 month low of $1.31 and a 12 month high of $27.35. The business's 50-day simple moving average is $1.97 and its 200-day simple moving average is $3.10.

Institutional Investors Weigh In On RAPT Therapeutics

A number of institutional investors have recently modified their holdings of RAPT. Acadian Asset Management LLC purchased a new position in shares of RAPT Therapeutics in the 1st quarter valued at $97,000. EntryPoint Capital LLC acquired a new stake in RAPT Therapeutics in the 1st quarter valued at $161,000. XTX Topco Ltd bought a new position in RAPT Therapeutics in the second quarter worth about $108,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of RAPT Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company's stock worth $148,000 after acquiring an additional 3,824 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its position in RAPT Therapeutics by 66.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company's stock worth $258,000 after purchasing an additional 33,692 shares during the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.